目的 探討腦安膠囊聯(lián)合艾地苯醌片治療急性腦梗死的臨床療效。方法 選取2020年1月—2021年12月湘潭醫(yī)衛(wèi)職院附屬醫(yī)院（湘潭市第三人民醫(yī)院）收治的80例急性腦梗死患者，根據(jù)隨機數(shù)字表法將80例患者隨機分為對照組和治療組，每組各40例。對照組患者口服艾地苯醌片，30mg/次，3次/d。治療組患者在對照組治療的基礎上口服腦安膠囊，0.8g/次，2次/d。兩組患者連續(xù)治療4周。觀察兩組的臨床療效，比較兩組的功能綜合評定量表（FCA）評分、美國國立衛(wèi)生研究院腦卒中量表（NIHSS）評分、低灌注區(qū)面積以及血清抗心磷脂抗體（ACA）、趨化因子配體12（CXCL12）、基質金屬蛋白酶8（MMP-8）水平。結果 與對照組（75.00%）相比，治療組的總有效率（92.50%）更高，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組的FCA評分顯著增大，NIHSS評分顯著減?。?i>P＜0.05）；治療組的FCA評分高于對照組，NIHSS評分低于對照組，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組的低灌注區(qū)面積均顯著縮?。?i>P＜0.05），治療組的低灌注區(qū)面積明顯小于對照組，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組的血清ACA、CXCL12、MMP-8水平均明顯降低（P＜0.05）；治療組的血清ACA、CXCL12、MMP-8水平均低于對照組（P＜0.05）。結論 腦安膠囊聯(lián)合艾地苯醌片治療急性腦梗死的療效確切，可改善神經功能，縮小低灌注區(qū)面積，降低血管內皮損傷，且藥物安全性良好。

Objective To investigate the clinical efficacy of Naoan Capsules combined with Idebenone Tablets in treatment of acute cerebral infarction. Methods Patients (80 cases) with acute cerebral infarction in the Affiliated Hospital of Xiangtan Medicine & Health Vocational College (the Third People's Hospital of Xiangtan) from January 2020 to December 2021 were divided into control and treatment groups according to random number table method, and each group had 40 cases. Patients in the control group were po administered with Idebenone Tablets, 30 mg/time, three times daily. Patients in the treatment group were po administered with Naoan Capsules on the basis of the control group, 0.8 g/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and FCA scores, NIHSS scores, the area of low perfusion area, the levels of ACA, CXCL12, and MMP-8 in two groups were compared. Results Compared with the control group (75.00%), the total effective rate of the treatment group (92.50%) was higher, and the difference was statistically significant (P<0.05). After treatment, the FCA score in two groups were significantly increased, but the NIHSS score in two groups significantly were decreased (P<0.05). The FCA score of the treatment group was higher than that of the control group, but the NIHSS score of the treatment group was lower than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the area of low perfusion area in two groups significantly were decreased (P<0.05), and the area of low perfusion area in the treatment group were significantly lower than that in the control group, with statistical significance (P<0.05). After treatment, the serum levels of ACA, CXCL12, and MMP-8 in two groups were significantly decreased (P<0.05), and the serum levels of ACA, CXCL12, and MMP-8 in the treatment group were lower than those in the control group (P<0.05). Conclusion Naoan Capsules combined with Idebenone Tablets has clinical curative effect in treatment of acute cerebral infarction, can improve the nerve function, reduce the area of low perfusion area, and reduce vascular endothelial injury, with good safety.

R971

湖南省衛(wèi)生健康委2020年度科研立項課題（20201196）